Chester County News and Community Website
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) recently reported new Phase 3 data showing sustained symptom improvement and reduced antibody levels in patients with generalized myasthenia gravis treated with …
Johnson & Johnson Reports Long-Term Data on Myasthenia Drug Read More
CONSHOHOCKEN, PA — Suvoda has introduced an artificial intelligence-driven system designed to reduce the time required to launch clinical trials, the company announced.
Suvoda Launches AI Tool to Speed Clinical Trial Startup Read More
KING OF PRUSSIA, PA — SEED Therapeutics, Inc. reported new preclinical data showing anticancer activity of its RBM39 degrader candidate ST-01156 in neuroblastoma and said the drug is being evaluated …
SEED Reports Preclinical Data on RBM39 Drug in Neuroblastoma Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will present early results from a Phase 1 clinical trial of its WEE1 inhibitor APR-1051 at the 2026 American Society of Clinical …
Aprea Abstract Accepted for ASCO on APR-1051 Phase 1 Study Read More
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) reported recently updated clinical data for its PBFT02 therapy in frontotemporal dementia and said it has initiated a strategic review process following …
Passage Bio Reports Trial Data, Reviews Strategic Options Read More
WASHINGTON, D.C. — Federal health officials are investing up to $139.4 million in new research to accelerate the development of mental health treatments, including emerging therapies such as digital tools, …
$139M Mental Health Push Aims to Speed New Treatments Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will present clinical results from its QTORIN™ rapamycin program at the ISSVA World Congress 2026 in Philadelphia, with data from Phase 3 …
Palvella to Present QTORIN Study Data at ISSVA 2026 Conference Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present Phase 1 clinical data for its investigational drug Teverelix at the American Association of Clinical Endocrinology Annual Meeting, …
Medicus Pharma to Present Phase 1 Data on Teverelix at AACE 2026 Read More
WASHINGTON, D.C. — Federal regulators are pushing thousands of companies and researchers to disclose missing clinical trial results, warning that gaps in reporting may distort how drugs and medical products …
FDA Presses Firms to Report Missing Clinical Trial Results Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present new Phase 1 clinical data on Teverelix, its investigational long-acting gonadotropin-releasing hormone antagonist, at the American Association of …
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting Read More